Rapport Therapeutics (NASDAQ:RAPP) Downgraded to “Sell” Rating by Wall Street Zen

Rapport Therapeutics (NASDAQ:RAPP) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

A number of other equities analysts also recently commented on the company. HC Wainwright increased their price objective on Rapport Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. The Goldman Sachs Group reiterated a “buy” rating on shares of Rapport Therapeutics in a research note on Friday, December 19th. BTIG Research boosted their target price on shares of Rapport Therapeutics to $47.00 and gave the stock a “buy” rating in a research report on Monday. Citigroup restated a “market outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. Finally, TD Cowen restated a “buy” rating on shares of Rapport Therapeutics in a report on Monday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.

Rapport Therapeutics Trading Down 2.9%

RAPP opened at $27.84 on Friday. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -9.73 and a beta of 1.51. Rapport Therapeutics has a 1 year low of $7.73 and a 1 year high of $42.27. The stock has a fifty day moving average price of $28.10 and a 200 day moving average price of $26.99.

Rapport Therapeutics (NASDAQ:RAPP) last issued its earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.07). As a group, sell-side analysts forecast that Rapport Therapeutics will post -3.65 earnings per share for the current fiscal year.

Insider Activity

In related news, COO Cheryl Gault sold 2,014 shares of the stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $28.93, for a total transaction of $58,265.02. Following the completion of the sale, the chief operating officer owned 169,914 shares in the company, valued at $4,915,612.02. This represents a 1.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Abraham Ceesay sold 5,083 shares of the firm’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $29.36, for a total transaction of $149,236.88. Following the completion of the sale, the chief executive officer owned 20,729 shares in the company, valued at approximately $608,603.44. The trade was a 19.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 69,669 shares of company stock valued at $1,999,877 over the last three months. 13.57% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Rapport Therapeutics

Hedge funds have recently made changes to their positions in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Rapport Therapeutics by 86.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,887 shares of the company’s stock worth $99,000 after buying an additional 4,582 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC bought a new stake in shares of Rapport Therapeutics in the 1st quarter worth approximately $2,039,000. Rhumbline Advisers grew its holdings in shares of Rapport Therapeutics by 40.1% during the 1st quarter. Rhumbline Advisers now owns 14,358 shares of the company’s stock worth $144,000 after purchasing an additional 4,109 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Rapport Therapeutics by 5.5% during the 2nd quarter. Geode Capital Management LLC now owns 333,159 shares of the company’s stock worth $3,789,000 after purchasing an additional 17,496 shares in the last quarter. Finally, Creative Planning acquired a new position in shares of Rapport Therapeutics in the second quarter valued at $121,000.

Key Stories Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: HC Wainwright raised multiple near‑term EPS forecasts for RAPP (Q1–Q4 2026 and FY2026) and lifted FY2027/FY2028 estimates, while maintaining a “Buy” rating and a $40 price target — supportive for upside if clinical or commercial progress continues. Read More.
• Neutral Sentiment: HC Wainwright posted a FY2030 EPS projection (longer‑range modeling) that is not an immediate driver of near‑term price action but signals analyst coverage continues to model multi‑year outcomes. Read More.
• Neutral Sentiment: A Globenewswire filing posted preparatory materials for a March 27 corporate meeting (annual report/AGM materials). This appears administrative and unlikely to be material to near‑term stock moves. Read More.
• Negative Sentiment: RAPP reported an earnings miss (reported March 10), which triggered a gap‑down and sell‑off; one article highlights the immediate downward reaction and higher trading volume as investors reprice near‑term performance risk. Read More.
• Negative Sentiment: Although many near‑term estimates were raised, HC Wainwright materially worsened its FY2029 EPS forecast (larger loss), which increases uncertainty about later‑stage profitability and may weigh on longer‑dated investor expectations. Read More.

About Rapport Therapeutics

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.